FDA withdraws Covid antibody treatment Evusheld because it’s not effective against 93% of subvariants - Earth News Report
In this articleAZNFollow your favorite stocksCREATE FREE ACCOUNT Evusheld (tixagevimab and cilgavimab) injection, a new COVID-19 treatment that people can take before becoming symptomatic. (Chris Sweda/Chicago Tribune/Tribune News Service via Getty Images)Chris Sweda | Tribune News Service | Getty Images The Food and Drug Administration on Thursday pulled its authorization for AstraZeneca's Evusheld, an antibody
